



VytOne Pipeline

Q2 2026

Pipeline News | New to Market Brands and Generics | Clinical Pipeline and Spotlight

April 2026

Spotlight | Pipeline News

Rybelsus rebranded to Ozempic® pill

- Rebranding aligns oral semaglutide with the established Ozempic name, improving recognition of available type 2 diabetes treatment options among patients and providers.
- The launch of the rebranded tablets is expected in Q2 2026.

Updates in GLP-1 weight loss market

- On April 7, 2026, Novo Nordisk launched Wegovy® HD as a single-dose pen. The new product is available through all channels where Wegovy can be accessed, including direct-to-consumer (DTC) platforms.
- On April 1, 2026, the FDA approved Eli Lilly’s Foundayo™ (orforglipron) to reduce excess body weight in adults with obesity or overweight. Annual Wholesale Acquisition Cost (WAC) of Foundayo is \$7,894 and the drug is available via DTC consumer sites.

GLP-1 Weight Loss Comparison		
Drug	Dose	Avg Body Weight Loss
Zepbound® injectable	15mg weekly	20.9%
Wegovy HD injectable	7.2mg weekly	18.8%
Wegovy injectable	2.4mg weekly	15.5%
Saxenda® injectable	3mg daily	7.4%
Wegovy tablet	25mg daily	13.6%
Foundayo tablet	36mg daily	11.2%

Direct-to-Consumer platform launched

- TrumpRx, the White House-backed DTC platform, launched on February 5, 2026.
- The platform does not dispense medications directly; it redirects patients to manufacturer-sponsored DTC sites or partner pharmacies offering discounted drug pricing.
- While the cash prices listed on the site are discounted, patients with insurance coverage may still pay less by using their insurance and paying the copay.
- Medications purchased through TrumpRx do not currently apply toward patient deductibles or out-of-pocket maximums; potential approaches to better link these payments to insurance coverage may be evaluated.
- As of April 1, 2026, the platform features 60+ drugs from 11 manufacturers, up from 40 products at launch.

Now Approved | New Brand Drugs to Market

Brand Name	Generic Name	Indication	ROA	Approval Month
AQVESME™	Mitapivat	Anemia	PO	Jan-26
CARDAMYST™	Etipamil	Paroxysmal supraventricular tachycardia	IN	Jan-26
DAYBUE® STIX	Trofinetide	Rett syndrome	PO	Jan-26
EXDENSUR™	Depemokimab	Severe asthma	SC	Jan-26
RYBREVANT® FASPRO	Amivantamab-hyaluronidase	Metastatic non-small cell lung cancer	SC	Jan-26
WEGOVY®	Semaglutide	Obesity; reduce risk of cardiovascular events	PO	Jan-26
LUNSUMIO® VELO	Mosunetuzumab	Follicular lymphoma	SC	Feb-26
MYGORZO™	Aficamten	Symptomatic obstructive hypertrophic cardiomyopathy	PO	Feb-26
PIVYA™	Pivmecillinam	Urinary tract infections	PO	Feb-26
YARTEMLEA™	Narsoplimab	Transplant-associated thrombotic microangiopathy	IV	Feb-26
ZYCUBO®	Copper histidinate	Menkes disease	SC	Feb-26
AUKELSO®	Denosumab	Prevention of skeletal-related events	SC	Mar-26
DESMODA™	Desmopressin	Management of central diabetes insipidus	PO	Mar-26
LOARGYS™	Pegzilarginase	Hyperargininemia	IJ	Mar-26
ORLADEYO®	Bertralstat	Prophylaxis to prevent attacks of hereditary angioedema	PO	Mar-26
REZENOPY™	Naloxone	Opioid overdose	IN	Mar-26
VYBRIQUE™	Sildenafil	Erectile dysfunction	PO	Mar-26
YUVEZZI™	Carbachol-brimonidine	Presbyopia	OP	Mar-26
YUWIWEL™	Navepegritide	Achondroplasia	SC	Mar-26

Now Approved | New Generic Drugs to Market

Brand Name	Generic Name	Indication	Launch Month
ECOZA®	Econazole nitrate	Interdigital tinea pedis	Oct-25
ENDOMETRIN®	Progesterone	Infertility	Oct-25
GRALISE®	Gabapentin	Pain associated with postherpetic neuralgia	Oct-25
RAVICTI®	Glycerol phenylbutyrate	Urea cycle disorders	Oct-25
VABRINTY®	Leuprolide acetate	Advanced prostate cancer	Oct-25
GLEOSTINE®	Lomustine	Hodgkin's lymphoma	Dec-25
MAVENCLAD®	Cladribine	Multiple sclerosis	Dec-25
PREMARIN®	Estrogens, conjugated	Hormone therapy	Dec-25
RYTARY®	Carbidopa and levodopa	Parkinson's disease	Dec-25
CIPRO HC®	Ciprofloxacin hydrocortisone	Acute otitis media	Jan-26
PREDNISON DR®	Prednisone	Inflammatory conditions	Jan-26
ZYLET®	Loteprednol-tobramycin	Inflammatory ocular conditions	Jan-26
BRIVIACT®	Brivaracetam	Seizures	Mar-26
EDURANT®	Rilpivirine	HIV-1 infection	Mar-26
NUCYNTA®	Tapentadol	Acute pain	Mar-26
POMALYST®	Pomalidomide	Multiple myeloma	Mar-26

The report provided is for informational purposes only. This information should not be solely relied upon for formulary decision-making purposes and is subject to change. www.vytlone.com
 Abbreviation: ROA- Route of Administration; IJ-Injection; IT-Intrathecal; IV-Intravenous; OP-ophthalmic; OR-Oral; PO-by mouth; SC-Subcutaneous

Clinical Pipeline

Bladder Cancer

Sasanlimab [Pfizer]

- A subcutaneous (SC) anti-PD-1 monoclonal antibody indicated for the treatment of treat high-risk, BCG-naïve non-muscular invasive bladder cancer (NMIBC).
- Paid under the medical benefit and positioned as a first-line immunotherapy for this population, addressing an area with limited recent therapeutic innovation with no new approved therapies in over 30 years.
- SC administration enables in-office delivery, offering a more convenient alternative to IV therapies that require infusion center visits.
- Annual treatment cost is expected to be \$200,000 to \$300,000, consistent with currently marketed PD-1 inhibitors.
- Regulatory decision anticipated in Q2 2026.

Breast Cancer

Vepdegestrant [Pfizer]

- This drug is an oral estrogen receptor (ER) proteolysis-targeting chimera (PROTAC) degrader to treat ESR1-mutant ER+/HER2- metastatic breast cancer following progression on a CDK4/6 inhibitor.
- If approved, vepdegestrant would be the first PROTAC-based endocrine therapy and may establish a new treatment class that is different than traditional selective ER degraders (SERDs).
- Annual WAC is estimated to be \$200,000 to \$300,000.
- Regulatory decision expected by June 6, 2026.

Gout

Pegadricase [Sobi]

- An intravenous combination product of pegadricase co-administered with ImmTor™ to mitigate the formation of anti-drug antibodies in patients with chronic refractory gout.
- If approved, will provide an alternative to Krystexxa®, which is dosed every two weeks.
- Granted Fast Track designation by the FDA.
- Annual WAC is expected to be \$500,000 to \$1,000,000.
- Regulatory decision is expected by June 27, 2026.

Thyroid Eye Disease

Veligrotug [Viridian Therapeutics]

- Thyroid eye disease (TED) causes inflammation behind the eye, leading to pain, bulging eyes, and possible blindness.
- Veligrotug is an intravenous monoclonal antibody that targets the insulin-like growth factor-1 receptor.
- Requires administration by a medical provider.
- Granted Priority Review by the FDA.
- Advantages over competing product Tepezza® is decreased infusion time (half to one-third of the time) and is given in five infusions versus eight.
- Therapy cost expected to be \$300,000 to \$500,000 per course.
- Regulatory decision expected by June 30, 2026.



Focus on

Indication Expansion

Indication expansions shaping late-stage pipeline

- Manufacturers continue to leverage indication expansion as a life-cycle management strategy. The current pipeline includes several high-impact therapies pursuing label expansion that may broaden eligible patient populations.
- In March 2026, Dupixent® received approval for allergic fungal rhinosinusitis while Sotyktu® expanded into psoriatic arthritis, potentially affecting utilization across additional indications.
- Planned or pending expansions – such as Stelara® in pediatric Crohn’s disease and Mounjaro® in pediatric type 2 diabetes – could introduce new first-in-class or competitive options within established categories.
- Overall, label expansions may extend brand utilization and product longevity while increasing therapy options for patients and influencing drug management strategies.

Indication Expansion Pipeline				
Drug	Current Indication(s)	Pending Indication	Route of Administration	Pending Approval Date
Stelara®	CD; UC; PsO; PsA	Pediatric CD	Intravenous/ subcutaneous	April 2026
Auvelity®	Major depressive disorder	Alzheimer’s disease agitation	Oral	April 30, 2026
Vyvgart®	Adults with gMG anti-AChR antibody-positive	Adults with gMG anti-AChR antibody-negative	Intravenous	May 10, 2026
Afrezza®	Glycemic control in adults with T1D or T2D	Glycemic control in children aged 4-17 with T1D or T2D	Inhaled	May 29, 2026
Leqembi® Iqlik	AD – maintenance dosing	AD – initiation dosing	Subcutaneous	Q2 2026
Mounjaro®	Glycemic control in adults with T2D	Improve glycemic control in children aged 10-18 with T2D	Subcutaneous	1H 2026

Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis; PsO, plaque psoriasis; PsA, psoriatic arthritis; gMG, generalized myasthenia gravis; AChR, anti-acetylcholine receptor; T1D/T2D, type 1 / 2 diabetes; AD, Alzheimer’s disease.

Spotlight

Plaque Psoriasis



Newly approved therapy provides first oral option for interleukin blockade

- Psoriasis affects more than 7.5 million adults in the United States with plaque psoriasis (PsO) accounting for approximately 80% to 90% of cases; treatment options for moderate-to-severe disease include oral systemic agents such as Sotyktu® (TYK2 inhibitor) and Otezla® (PDE4 inhibitor) as well as injectable biologics targeting TNF, IL-23, and IL-17 pathways, which remain standard of care.
- Icotyde® (icotrokinra) is an oral IL-23 receptor antagonist approved on March 17, 2026, for the treatment of moderate-to-severe plaque psoriasis in adult and pediatric patients aged 12 years and older. While this provides the first non-injectable IL-pathway option, some patients and providers may continue to prefer biologics due to extended dosing intervals and established long-term efficacy.
- Estimated annual WAC is approximately \$100,800, comparable to Tremfya® and several other PsO therapies.

Newly approved therapy provides first oral option for interleukin blockade

The plaque psoriasis pipeline remains active with both novel therapies and existing products advancing through development or seeking approval. Non-biologic as well as biologic treatments for plaque psoriasis represent a significant share of specialty drug spending in the U.S. Ongoing pipeline developments may further influence treatment options and overall spend in this space.

Novel Plaque Psoriasis Therapies in Pipeline			
Drug	Route	Mechanism	Potential approval
TAK-279 (zasocitinib)	Oral	TYK2 inhibitor	2H27
SFA-002	Oral	Immunomodulator	2H27
Orismilast	Oral	PDE4 inhibitor	2027+
ESK-001 (envudeucitinib)	Oral	TYK2 inhibitor	2H27
CF101 (piclidenoson)	Oral	Adenosine A3 receptor agonist	2H28

Abbreviations: TNF, tumor necrosis factor; IL, interleukin; TYK, tyrosine kinase; PDE, phosphodiesterase